Cardiol Therapeutics Inc. (CRDL.TO)

2.4000 -0.0900 (-3.61%) As of 12:08PM EDT. Market open.

Cardiol Therapeutics Inc.

2265 Upper Middle Road East
Suite 602
Oakville, ON L6H 0G5
Canada
289-910-0850
https://www.cardiolrx.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. David G. Elsley MBA	President, CEO & Director	748.1k	N/A	N/A
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA	CFO, Corporate Secretary & Director	294.8k	N/A	N/A
Mr. Bernard Lim B.Sc.	Chief Operating Officer	515.9k	N/A	N/A
Dr. Andrew Warwick Hamer M.D.	Chief Medical Officer & Head of Research & Development	746.56k	N/A	1962
Trevor Burns	Investor Relations	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Corporate Governance

Cardiol Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.